Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.78)
# 3,350
Out of 5,046 analysts
60
Total ratings
47.62%
Success rate
-2.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Maintains: Neutral | $27 → $30 | $31.86 | -5.84% | 6 | Oct 21, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $157 → $139 | $113.76 | +22.19% | 10 | Oct 17, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $20 → $24 | $19.99 | +20.06% | 6 | Sep 18, 2025 | |
| GERN Geron | Reinstates: Sell | $1 | $1.26 | -20.63% | 4 | Jul 10, 2025 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $34.78 | -36.75% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $8.74 | +71.62% | 2 | May 14, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $4.05 | +220.99% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $28.57 | -2.00% | 7 | Jan 9, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $2.05 | +3,021.95% | 6 | Aug 15, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $216 → $184 | $30.21 | +509.07% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $2.52 | +733.33% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $8.26 | +69.49% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $160 | $4.16 | +3,750.78% | 2 | Dec 15, 2021 |
IDEAYA Biosciences
Oct 21, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $31.86
Upside: -5.84%
Rhythm Pharmaceuticals
Oct 17, 2025
Maintains: Buy
Price Target: $157 → $139
Current: $113.76
Upside: +22.19%
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $20 → $24
Current: $19.99
Upside: +20.06%
Geron
Jul 10, 2025
Reinstates: Sell
Price Target: $1
Current: $1.26
Upside: -20.63%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $34.78
Upside: -36.75%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $8.74
Upside: +71.62%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $4.05
Upside: +220.99%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $28.57
Upside: -2.00%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $2.05
Upside: +3,021.95%
RAPT Therapeutics
Mar 15, 2023
Maintains: Buy
Price Target: $216 → $184
Current: $30.21
Upside: +509.07%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $2.52
Upside: +733.33%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $8.26
Upside: +69.49%
Dec 15, 2021
Initiates: Neutral
Price Target: $160
Current: $4.16
Upside: +3,750.78%